| Description | ARN2966 is an inhibitor of amyloid precursor protein (APP)and amyloid-β (Aβ) secretion. |
| In vitro | ARN2966 reduces levels of APP and its intracellular C-terminal fragments α-CTF and β-CTF in CHO APP751SW cells when used at a concentration of 10 μM. ARN2966?also reduces?secretion of Aβ (1-40) and Aβ (1-42) by 88.6 and 84.9%, respectively. |
| In vivo | In vivo,ARN2966? reduces brain levels of full-length APP, α-CTF and β-CTF, and soluble Aβ (1-40) and Aβ (1-42) in the APPSWPS1dE9 transgenic mouse model of Alzheimer's disease.?It also improves novel object memory as well as spatial memory in the radial arm maze in APPSWPS1dE9 transgenic mice. |
| molecular weight | 200.24 |
| Molecular formula | C12H12N2O |
| CAS | 102212-26-0 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 55 mg/mL (274.67 mM), Sonication is recommended. |
| References | 1. Asuni A A . Modulation of APP Expression Reduces Aβ Deposition in a Mouse Model.[J]. Annals of Neurology, 2014, 75(5):684. |